Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450939 | 1.00 | APAF1 (0.54) | APAF1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL27929812 | 1.00 | APAF1 (0.54) | APAF1ALDH1A1KMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL10481434 | 0.98 | ALDH1A1 (0.54) | APAF1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL13484773 | 0.89 | KMT2A (0.53) | ALDH1A1KMT2AMEN1MAPTANPEP | |
| SCHEMBL11298432 | 0.88 | APAF1 (0.44) | APAF1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL13484519 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1MAPTANPEP | |
| SCHEMBL23102214 | 0.84 | MAPT (0.55) | ALDH1A1KMT2AMEN1MAPTANPEP | |
| SCHEMBL12548382 | 0.84 | MAPT (0.55) | ALDH1A1KMT2AMEN1MAPTANPEP | |
| SCHEMBL1161723 | 0.84 | MAPT (0.55) | ALDH1A1KMT2AMEN1MAPTANPEP | |
| SCHEMBL11510651 | 0.84 | ANPEP (0.54) | APAF1ALDH1A1ANPEPCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105151-A1 | IMPROVED IN-SITU SYNTHESIS OF AMINO METHYL PROPANOIC ACID | OPTICELLAR INNOVATION PRIVATE LIMITED (IN) | 2026-05-21 | — | — | WO | claimed |
| WO-2026105151-A1 | IMPROVED IN-SITU SYNTHESIS OF AMINO METHYL PROPANOIC ACID | OPTICELLAR INNOVATION PRIVATE LIMITED (IN) | 2026-05-21 | — | — | WO | disclosed |
| CN-106458996-B | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3097092-B1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3097092-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| CN-103980204-B | Ionic liquid-catalyzed amine and α, β-unsaturated electron deficiency receptor method | TAIZHOU UNIVERSITY (CN) | 2016-03-30 | — | — | CN | disclosed |
| WO-2015109285-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| CN-103980204-A | Method for catalyzing amines and alpha, beta-unsaturated electron-deficient acceptors by ionic liquid | UNIV TAIZHOU | 2014-08-13 | — | — | CN | disclosed |
| US-4481360-A | 4H-1,2,4-Triazol-3-yl compounds | THE UPJOHN COMPANY (US) | 1984-11-06 | — | — | US | disclosed |
| US-3886145-A | NEW DERIVATIVE OF TRIAMCINOLONE | SIGMA-TAU INC. | 1975-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | APAF1 3452/4885ALDH1A1 3652/4885KMT2A 3453/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | APAF1 4314/4885ALDH1A1 4827/4885KMT2A 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.